Henry Ji, Ph.D., Chairman

Henry Ji, Ph.D. co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012.

Dorman Followwill

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016.

 | read more »

Kim D. Janda, Ph.D.

Dr. Janda has served as a director since April 2012. Dr. Janda has been the Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute (“TSRI”) since 1996 and as the Director of the Worm Institute of Research and Medicine (“WIRM”) at TSRI since 2005. Furthermore, Dr. Janda has served as a Skaggs Scholar within the Skaggs Institute of Chemical Biology, also at TSRI, since 1996.

 | read more »

David Lemus

David Lemus, age 54, currently serves as a non-executive board member of BioHealth Innovation, Inc., The MIT Club of Washington DC and Proteros BioScience GmbH. From January 2016 to May 2017, he served as Interim Chief Financial Officer and Chief Operating Officer of Medigene AG, a publicly-listed German biotechnology company focused on the research and development of T-Cell-Receptor based immunotherapies.

 | read more »

Jaisim Shah

Mr. Shah currently serves as the Chief Executive Officer and board member at Semnur Pharmaceuticals. Prior to Semnur, Mr. Shah was a consultant to several businesses, including Sorrento Therapeutics. From 2011 through 2012, Mr. Shah was the Chief Business Officer of Elevation Pharmaceuticals. Prior to Elevation, Mr. Shah was President of Zelos Therapeutics, where Mr. Shah focused on financing and business development.

 | read more »

Yue Alexander Wu, Ph.D.

Dr. Wu is co-founder, President, Chief Executive Officer and Chief Scientific Officer of Crown Bioscience International, a leading global drug discovery and development solutions company, which he co-founded in 2006. From 2004 to 2006, Dr. Wu was Chief Business Officer of Starvax International Inc. in Beijing, China, a biotechnology company focusing on oncology and infectious diseases. From 2001 to 2004, Dr. Wu was a banker with Burrill & Company where he was head of Asian Activities. Dr. Wu received his Ph.D. in Molecular Cell Biology and his MBA from University of California at Berkeley. He earned an M.S. in Biochemistry from University of Illinois, Urbana-Champaign and his B.S. in Biochemistry from Fudan University in Shanghai, China.